Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GB-AF-023
- Development stage
- Preclinical
- Lead developer
- GAT Biosciences
- Modality
- Small Molecules, Antibody-Based Therapeutics
- Administration
- Oral
01
Overview
GB-AF-023 is an investigational oral therapeutic candidate developed by GAT Biosciences for the treatment of Inflammatory Bowel Disease (IBD). It is designed to target and inhibit Tumor Necrosis Factor-like Ligand 1A (TL1a), a cytokine belonging to the TNF superfamily that is a key mediator of mucosal inflammation and intestinal fibrosis. By neutralizing TL1a activity, GB-AF-023 aims to provide a targeted anti-inflammatory effect within the gastrointestinal tract. The program is currently in the discovery and preclinical stages, with the developer exploring oral delivery modalities, which may include either an oral biologic (such as an antibody) or a small molecule inhibitor.
02
Targets
Beyond the preview
Go deeper on GB-AF-023.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GB-AF-023.